Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Date:4/21/2009

sion (abstract #3594) during the American Association for Cancer Research's 100th Annual Meeting 2009 at the Colorado Convention Center in Denver.

Phase 1 Study Design and Results

Poniard's randomized, open-label, dose-ranging Phase 1 study was conducted at clinical sites in the United States. The trial compared the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously to patients with advanced solid tumor malignancies. Bioavailability refers to the fraction of an administered dose of an unchanged drug that reaches systemic circulation. In the first part of this two-part trial, patients with advanced solid tumor malignancies were randomized to a single dose of either intravenous (120 mg/m squared) or oral picoplatin (200 mg, 300 mg or 400 mg). Four weeks later, they received a second single picoplatin dose administered via the other route. In the second part of the trial, patients received only a single oral dose of picoplatin (including doses of 50 mg and 100 mg).

Final results showed that oral picoplatin achieved oral bioavailability of nearly 100 percent at doses of 50 mg and 100 mg. No meaningful differences in pharmacokinetics were observed between the two formulations. All doses of the oral dose were well tolerated. No serious adverse events related to treatment were noted following administration of the oral dose.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other pl
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... ... Cambridge Consultants that discussed how innovation and technology would be the “key factors” ... to address issues of accessibility and affordability, especially in emerging and growing markets. ...
(Date:7/7/2015)... , ... July 07, 2015 , ... Today, the physicians ... major medical facilities in Orange and San Bernardino counties, released a series of tips ... particularly hazardous time of year for children, who spend more unsupervised time outdoors. ...
(Date:7/7/2015)... ... July 07, 2015 , ... Leading healthcare consulting ... Warden as Senior Vice President, heading the firm’s Healthcare Advisory Services division. , ... solutions to healthcare providers’ needs in ways that strengthen their position in the ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Difass USA, ... can help pass those long, stressful days at work is knowing that there is ... as laid back and stress free as imagined. Planning for a vacation can be ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... firms have merged to form Camber Collective. Camber Collective provides strategic advisory ... combines SwitchPoint’s strategy consulting expertise with Hope Consulting’s deep experience in customer ...
Breaking Medicine News(10 mins):Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 2Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 3Health News:Allied Anesthesia Physicians Release Summertime Safety Tips 2Health News:Allied Anesthesia Physicians Release Summertime Safety Tips 3Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2
... Awareness, Education about Bone Disease, HARRISBURG, ... the bone-weakening disease osteoporosis, the Pennsylvania,Commission for ... Association,and Pennsylvania Dairy Promotion Program to launch ... Cameron, Clinton, Juniata,Perry, Sullivan, and Tioga counties., ...
... Public Relations,has been retained by Diagnostic Centers of America ... a revolutionary breakthrough in cardiac,and diagnostic medical imaging, enabling ... time than it takes to beat and without the ... following the installation of the new SOMATOM,Definition dual source ...
... For most people, the significant,downtime involved in undergoing ... signs of aging skin is not realistic given ... minimally invasive,laser skin resurfacing technologies are delivering noticeable ... without spending weeks under,wraps, as is common with ...
... activities to improve balance , , SUNDAY, Feb. 3 (HealthDay News) ... seniors over age 65, and almost one in two over ... in some cases, leading to serious disability or even death. ... reduce their risk of falls are expected to be discussed ...
... poor thwart reaching 2010 benchmark , , SATURDAY, Feb. 2 ... will fall far short of its benchmark goals toward ... and Nutritional Examination Survey data. , Researchers found that ... U.S. population in 1999-2000 was 4.2 percent. This does ...
... iVillage Take Women,s Pulse on Key,Issues at ,How She ... AARP, which is,marking its 50th Anniversary, and iVillage, the ... of engaged, diverse women for the,groundbreaking "How She Will ... and providing a real-time pulse check of the issues ...
Cached Medicine News:Health News:PA Commission for Women Announces 'Shocking Pink' Osteoporosis Campaign in Rural PA 2Health News:Diagnostic Centers of America Retains NewsMark Public Relations to Showcase Its Rise as Only Medical Facility in South Florida With World's Most Advanced Cardiac Scanner 2Health News:Keep Father Time From Marching On: New Laser Treatments Offer Gentle and Effective Skin Resurfacing in a Flash 2Health News:Keep Father Time From Marching On: New Laser Treatments Offer Gentle and Effective Skin Resurfacing in a Flash 3Health News:Keep Father Time From Marching On: New Laser Treatments Offer Gentle and Effective Skin Resurfacing in a Flash 4Health News:Toll-Free Hotline to Help Seniors Avoid Falls 2Health News:U.S. Unlikely to Meet Target for TB Elimination 2Health News:Women Believe Economy Is Top Issue in 2008 Election 2Health News:Women Believe Economy Is Top Issue in 2008 Election 3
(Date:7/7/2015)... , 7. Juli 2015 BioClinica®, ... für klinische Studien, gab heute bekannt, dass es ... Unternehmen bei Gewinnung und Erhalt von Patienten übernommen ... MediciGlobal , Ltd. und Access to Patients, ... einen Dienst zum Auffinden von Patienten, die für ...
(Date:7/7/2015)... , July 7, 2015 /PRNewswire/ -- Mindray Medical ... leading developer, manufacturer and marketer of medical devices ... the remaining stake in Wuhan Dragonbio Surgical Implant ... Dragonbio is a domestic medical orthopedic-product ... other surgical products. Prior to today,s announcement, Mindray ...
(Date:7/7/2015)... , July 7, 2015 Oasmia ... drugs within human and veterinary oncology, has filed a ... Exchange Commission, in connection with the proposed public offering ... Market. The number of American Depositary Shares, representing ordinary ... the offering have not yet been determined. An Investor ...
Breaking Medicine Technology:BioClinica übernimmt MediciGroup 2BioClinica übernimmt MediciGroup 3BioClinica übernimmt MediciGroup 4Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow 2
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
Medicine Products: